Puvi Seshiah, MD
Interventional Cardiology · Cincinnati, OHNPI 1851396428
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (36.1%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Medtronic accounts for 82.2% of it on its own, with 19 other manufacturers making up the rest. 2025 is the largest year on record at $58,925, more than ten times the $384 reported in 2019.
Across 226 payments — averaging $359.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$67K
- Edwards Lifesciences$6K
- Abbott$3K
- Shockwave Medical, Inc$2K
- Ancora Heart, Inc.$2K
- Boston Scientific$761
- plus $1K from 14 others
Across 76 payments — averaging $2082.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$58K
- Edwards Lifesciences$54K
- Abbott$47K
What the payments were for
- Consulting fees$15,36919%
- Speaking & faculty fees$29,35636%
- Travel & lodging$29,15836%
- Food & beverage$7,3729%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 120 | $66,785 |
| Edwards Lifesciences | 27 | $5,600 |
| Abbott | 31 | $2,780 |
| Shockwave Medical, Inc | 1 | $2,200 |
| Ancora Heart, Inc. | 6 | $2,123 |
| Boston Scientific | 10 | $761 |
| Abiomed | 5 | $277 |
| Jenavalve Technology, Inc. | 1 | $175 |
| Biotronik Inc. | 4 | $168 |
| Siemens Medical Solutions USA, Inc. | 3 | $144 |
| Johnson & Johnson | 4 | $56 |
| E.r. Squibb & Sons, L.L.C. | 4 | $55 |
| AstraZeneca | 3 | $39 |
| Cardiva Medical, Inc. | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $14 |
| W. L. Gore & Associates, Inc. | 1 | $13 |
| Novo Nordisk | 1 | $13 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $12 |
| Gilead | 1 | $12 |
| Reflow Medical Inc | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- APOLLOTM$15,471
- Edwards SAPIEN 3 Transcatheter Heart Valve$3,750
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$2,200
- AccuCinch$2,123
- MitraClip$401
- XIENCE SIERRA$166
- Resolute$160
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$158
- ONYX FRONTIER$154
- MitraClip System$153
- Impella$150
- GENERAL - STENTS$150
- CoreValve Evolut$143
- COREVALVE EVOLUT R$142
- PASCAL$135
- MAMBA$130
- Watchman$125
- ABSOLUTE PRO$118
- SPECT Symbia Evo$105
- WATCHMAN Access System$102
How this compares
$81,255 in reported general payments places this provider in the 85th percentile of 256 interventional cardiology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 256 | $304,111 |
| EntrestoSacubitril/Valsartan | 133 | $151,606 |
| FarxigaDapagliflozin Propanediol | 53 | $58,350 |
| XareltoRivaroxaban | 47 | $50,377 |
| JardianceEmpagliflozin | 46 | $49,131 |
| Repatha SureclickEvolocumab | 57 | $35,006 |
| Praluent PenAlirocumab | 28 | $20,758 |
| Ranolazine ErRanolazine | 50 | $4,815 |
| Rosuvastatin Calcium | 445 | $4,129 |
| Ezetimibe | 218 | $4,073 |
| Metoprolol Succinate | 346 | $3,462 |
| Atorvastatin Calcium | 342 | $3,118 |
| Valsartan | 73 | $1,740 |
| ClopidogrelClopidogrel Bisulfate | 145 | $1,572 |
| Losartan Potassium | 167 | $1,337 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $39 | $58,35053 claims |
| Johnson & JohnsonXarelto | $56 | $50,37747 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 256 interventional cardiology providers in Ohio.
Other interventional cardiology in Cincinnati
- Timothy HenryCincinnati$605K
- John CorlCincinnati$390K
- Santiago GarciaCincinnati$360K
- Joseph ChooCincinnati$224K
- Dean KereiakesCincinnati$139K
- Ian SarembockCincinnati$98K
- Raviteja GuddetiCincinnati$68K
- Satya ShreenivasCincinnati$47K
- Amer SayedCincinnati$31K
- Zaid AlirhayimCincinnati$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.